Phase I part will last from 3 to 18 months (permitting the enrolment of minimum of 6 patients). The Phase I will be stopped after the RP2D is established. The Phase II will stop after the inclusion of 42 evaluable patients. All patients will be followed up for up to 12 months after end of treatment.